Announcement on Conversion Result of Convertible Bonds and Share Changes
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
Announcement on Conversion Result of Convertible Bonds and Share Changes
Filed with SSE · · 3 pages · Chinese
Release
Shenzhen Chipscreen Biosciences Co. Ltd. on 6ix
Earlier from Shenzhen Chipscreen Biosciences
- Announcement on Resolutions of the 25th Meeting of the 3rd Board of Directors
- Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Clinical Trials of Siglitazone Sodium and Metformin Hydrochloride Extended-Release Tablets
- Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Clinical Trials of CS08399 Tablets
- Announcement on Initially Repurchasing the Company's Shares through Call Auction
- Announcement on Obtaining Letter of Commitment for Special Loans for Stock Repurchase from Financial Institution
Later from Shenzhen Chipscreen Biosciences
- Announcement on Resolutions of the 2025 Annual General Meeting
- Indicative Announcement on the Adjustment of Convertible Bond Conversion Prices and Continuous Suspension for Convertible Shares during the Implementation of 2025 Annual Dividend Distribution
- Report for Q1 2026
- Announcement on Convening the Q1 2026 Performance Briefing
- Announcement on Adjusting the Conversion Price of "Chipscreen Convertible Bonds" Due to the Implementation of the 2025 Annual Profit Distribution and Resumption of Trading After Conversion Suspension
Follow Shenzhen Chipscreen Biosciences into a list and get an email when it puts out news.
Follow Shenzhen Chipscreen Biosciences